620
www.onkologiecs.cz3408040010765133201214262311348396415464514532576617652669709748
/39168040010732
Onkologie.39938040010760109147194214262312331375389
2024;18(5):318-3214402804001074487128168183220259283325348363407446485513554595634
/50818040010732
ONKOLOGIE51598040010760120167227269329388409453
32156558020012657113167
PŘEHLEDOVÉ4549200012660124182256312369444520587645
ČLÁNKY5216200012660115187259327395
Inovace37943600106155697134171204236
a4046360010638
vývoj410036001063675115154177
v4293360010636
terapii43453600106306298139174191208
chronické456936001063374109150192209244279312
lymfocytární489636001062962116146187223261296332367409426
leukemie533836001062961102137170225242273
19.340630085366982
Sharpe4376300833270103124164199
C,6516300834053
Davis7196300834578109125151
J,8856300832436
Mason9376300835487113151190
KD,1142630083358293
et12506300833456
al.1321630083324760
More13966300835593115149
Than15606300833272104142
a171763008332
BTK17646300833569105
Inhibitor;1884630083155391106340730083395477114135149
Ibrutinib503730083155476114136152190205244
Profoundly761730083355693113150188226265281313
Impacts10887300831573112145177201229
the1331730083226095
Function14417300833268106138163178216254
of17107300833756
Cell1781730083407389104
Mediated19007300835489340830083385385107141180
Immunity.5368300831472130168206221243277287
Blood.838830083365189128168181
2018;132(Supplement10348300833468100131143173203236253285322362401417452510545583604
1):4417-4417.165483008334486095132162191210247283314343349
20.340930085367186
Thangavadivel4409300833371103140178210241273311326358391406
S,8609300833345
Mao9199300835587124
C,10579300834053
Long11249300833168106144
M,12829300835567
et13649300833455
al.1433930083324759
T150693008333
Cell1553930083407388103
Dysfunction16709300834577104123161198230253268305343
and34010300833269107
Exhaustion45810300833264101133169195217231268306
in77510300831451
Patients8381030083356586101134171192219
with10681030083506586124
CLL:120310300834070101114
The132810300833371105
Impact144410300831572110142173196
of165110300833756
Long171810300833168105143
Term18721030083336283140
Ibrutinib3401130083155273110131145181195233
Treatment.5841130083324881112132189222259279291
Blood.8861130083355087124162174
2023;142(Supplement10711130083346698131142171200231248278314352390405438494528565585
1):4631-4631.1667113008334475891126158188205240275308337345
21.3401230085367082
de43712300833873
Weerdt52512300835891126148186208
I,74912300831427
Hofland79212300834482100117149187226
T,103312300833342
de109012300833873
Boer117912300833573109130
R,132412300833650
et138912300833456
al.14611230083324760
Distinct15361230083466187110126164196220
immune177112300831573130168206241
composition34013300833168125164203229244266281319357
in70913300831552
lymph77413300831546104143181
node96813300833775114149
and113013300833169108
peripheral12501330083397495110149187222243275291
blood15531330083395492130170
of173513300833756
CLL180413300834071103
patients1919133008339713401430083223772110131159
is51614300831541
reshaped5741430083215582120152191227266
during8581430083387596112150189
venetoclax106414300833266104139162198231246279310
treatment.13921430083214377109130188223262283296
Blood17061430083355189128167
Adv.189114300834179111121
2019;3(17):2642-2652.34015300833468100130143178196228257277289324357394426447478511545578591
22.3401630085367288
Kater4431630083356890124145
AP,6031630083417782
Eichhorst7001630083324779117155193215242265
B,98116300833548
Owen104416300834799133172
C,123116300834053
et129916300833456
al.13701630083324760
Long-Term144616300833168107146168198229250308
Host177016300834482109132
Immune19171630083157334017300835794131165
Changes51817300833976108145184218244
Following774173008332698499137187202239277
Treatment10641730083324982113135192226264285
with13611730083506587125
Venetoclax149817300833567105139161197229244275306
Plus18171730083344986111
Rituximab1941173008335503401830083226091106164196236
in59318300831452
Relapsed/Refractory6621830083367186118158184219259285322357376398431463487524546580
Chronic12591830083407799136174189221
Lymphocytic149718300833260119158196235267301326341373
Leukemia.18871830083316610334019300833064122137169182
Blood.5371930083365290128168181
2022;140:Supplement73319300833569102136149179210246259292330369409424459517552590612
1:7010-7012.13601930083344376109141173196228261293322335
23.3402030085367287
Langerbeins44120300833165103142177198238273288326353
P,80720300833539
Zhang85920300833876108146185
C,105720300834053
Robrecht112320300833674114135169202240261
S,139820300833245
et145620300833456
al.15252030083324760
The159820300833372107
CLL12171820300834072104133163
trial:1894203008322445991107119
ibrutinib3402130083155475114136151189204243
vs59921300833259
placebo6732130083395487119153192231
in91921300831553
treatment-naïve,9872130083224377109131189224262283303342374389422456468
early-stage14712130083346587102134156183206239278313
chronic17992130083327091128166181213
lymphocytic34022300831547105144183221254287312328359
leukemia.7152230083154987117151209225256270
Blood.10002230083355189128168181
2022;139(2):177-187.119622300833468101136148178208242261295313325354384418437468499532538
24.3402330085367186
Rogers44623300833574113148169197
KA,6622330083357994
Zhao77523300833876108146
Q,94123300834761
Bhat102123300833674106128
SA,11692330083327387
et127623300833456
al.13522330083324760
Extended14322330083336589123161200235275
Follow17262330083337086101139190
up193623300833776
of34024300833757
a415243008331
Phase46524300833572104131166
2649243008334
Study7012430083335492131163
of88224300833757
Early9572430083326586102134
Intervention11092430083155374108129164198237258273311350
with14772430083506688127
Lenalidomide162224300833165103136151166205243301316355390
in34025300831553
Patients4122530083366789105139177199227
with6582530083516789127
High-Risk8052530083445998136159196211237267
Chronic10922530083407899136175190222
Lymphocytic133425300833160118157196234267300325341372
Leukemia.172625300833266104134168226241273286
Blood.3402630083355189128168181
2023;142(Supplement53626300833468101136147177208241258290328367406422457515550588610
1):3272-3272.1161263008334486096128161195216248281314348361
25.3402730085367287
Al-Sawaf4412730083415679110143194227245
O,70027300834758
Zhang77127300833876108146185
C,97027300833952
Jin10362730083243977
HY,11262730083448089
et122827300833456
al.12982730083314760
Transcriptomic13712730083335083121147179201216255277314373388420
profiles18042730083396098115132147182209
and34028300833169107
5-year4602830083345586120152172
results6452830083205480117132154181
from8382830083184077134
the9852830083215993
randomized10902830083215391129167224239268301340
CLL14144228300834071102132162
study16172830083254886124155
of178528300833756
venetoclax1853283008331651031373402930083225991107139170
plus5272930083385492118
obinutuzumab6612930083377792130168190228258296354386425
versus11022930083326688115152178
chlorambucil12972930083316984122144177235274312344359374
plus16882930083385492118
obinutuzumab182229300833777931301683403030083226089127185217256
in60930300831553
chronic6753030083316990127166181213
lymphocytic90130300831446105144182220253287311327359
leukemia.12733030083144987117151209224256269
Nature15553030083457799137158192
Communications.1760303008340771351932303403130083385385117139154192231257271
2023;14(1):2147.62431300833468101136147177209228260274286321353384416422
26.2140630085367187
Niemann2240630083456095152185223261
CU,2514630083408495
Munir26226300835492130145166
T,28016300833342
Moreno28566300835493114148186225
C,30946300834053
et31606300833456
al.3229630083324760
Fixed-duration3302630083334779113152174215252273306328344381420
ibrutinib–venetoclax37356300831554214073008321598297135150189227260294332367390427459475507539
versus2699730083326687115152178
chlorambucil–obinutuzumab2898730083316985123145178236275313345361376412452492508546583606644673712770802841
in37607300831553
previously2140830083385992123138175212237252282
untreated2434830083377494115148179200232271
chronic2717830083306787123161175206
lymphocytic29358300831545102140178215247279303317348
leukaemia3295830083154985114147181237251282
(GLOW):3589830083186091135192212223
4-year2140930083345687120151172
follow-up232493008318557085122172193231269
from2606930083183975133
a275193008331
multicentre,27949300835793108130144175208246266287320332
open-label,31389300833775110147169185216254289304316
randomised,3466930083205289128165222236262296334347
phase214010300833977109136171
32326103008335
trial.2376103008321435991106119
The251010300833372107
Lancet263210300833265103135169191
Oncology.283910300834785117154170208248280290
2023;24(12):1423-1433.314410300833469101136148183214234266296313325355386419454475506537570603615
27.21401130085367180
Thompson223411300833372110168208234273311
PA,25591130083357387
Bazinet26601130083366898114152187209
A,288311300834155
Wierda295311300835773108129167199
WG,3167113008357101114
et329611300833356
al.33661130083324760
Sustained34401130083337097120153168206241280
remissions37341130083215521401230083577299125140178216243
in239912300831553
CLL246812300834072104
after25881230083325176110131
frontline27351230083194178117138154169207242
FCR299312300833273108
treatment31181230083214377109130189224262283
with34181230083506688127
very35611230083326687121
long-term3699123008315539121401330083386083117138196
follow-up.2352133008318567187125176198237276288
Blood.26561330083355189128167180
2023;blood.2023020158.285213300833468101136147186202240279319332368402435470504537571603633667681
28.21401430085367288
Stilgenbauer2243143008332546984123158196235268306341362
S,262014300833245
Eichhorst26801430083334880118156194216243266
B,296114300833548
Schetelig302414300833365103138160194210224263
J,330214300832437
et335414300833456
al.34251430083324760
Venetoclax350014300833668106141164201233249281312
for21401530083185678
Patients22371530083356788104138176198226
With24821530083577396134
Chronic26351530083407899136175190222
Lymphocytic287615300833159118157196234267300325340372
Leukemia326715300833266104134168226241273
With35591530083577396134
17p371215300833464100
Deletion:21401630083458196131153169207245257
Results24111630083357097134150172200
From26241630083325289148
the27851630083226095
Full2894163008332688499
Population300616300833572112150165197219234272311
of333016300833857
a3401163008331
Phase344616300833572105131166
II362616300831530
Pivotal3669163008335508312021401730083225470
Trial.2225173008333506698113126
J2366173008324
Clin24061730083405570108
Oncol.252917300834786118155171183
2018;36(19):1973-1980.272517300833468100131143178213232263294311323353383416450472503533568604616
29.21401830085367184
Tam223718300833260117
CS,23671830083397385
Brown24651830083355692143181
JR,26581830083246074
Kahl274418300833568105120
BS,28771830083356779
et296918300833355
al.30371830083314659
Zanubrutinib310918300833770107144183204242264279316331370
versus34911830083326586113150176
bendamustine367918300833874111214019300833870128166192215231268303
and245719300833270109
rituximab2580193008321365997128144201234273
in286719300831452
untreated29331930083377597118152184206240279
chronic32261930083316990128166181213
lymphocytic345319300831547105144183221254287312327359
leukaemia21402030083155190120155191250266298
and246020300833271111
small259220300832786119135151
lymphocytic276420300831548108148187226260294320336369
lymphoma315420300831548107148187226286319
(SEQUOIA):34942030083195285134179228244287306318
a2140213008332
randomised,21882130083205391130168227242268303342355
controlled,255921300833168107128149187203218253292305
phase288021300833877109136171
33066213008334
trial.3116213008322435991106119
The325121300833272107
Lancet337321300833265103136169191
Oncology.35802130083478611815517120921402230083387080
2022;23(8):1031-1043.223622300833468101135148183217236269287299329360394424443474505542574587
30.21402330085367186
Woyach223823300835793123156187225
JA,24752330083246377
Perez25642330083356889122151
Burbano27272330083357393132165202240
G,297923300834356
Ruppert304823300833572110149184205229
AS,32892330083417487
et338823300833455
al.34562330083314659
Follow-up3527233008332698499136187208247285
from21402430083184078136
the22912430083226095
A041202240124300834175111142172206239
study26552430083264987126158
shows282924300832663102153180
continued302424300833168107128144181219254293
efficacy3333243008334527088120153185218
of356724300833756
ibrutinib3639243008314537511313615121402530083385392
regimens22492530083215595110167202241267
for25332530083195678
older26292530083375392127148
adults279425300833271109124146174
with29862530083506688126
CLL.313025300834071103117
Blood.32652530083355189128167180
2024;143(16):346325300833468101133145175206239257288319337349
1616-1627.21402630083346596127150181212246278285
31.21402730085366982
Sharman224227300833371103124183216254
JP,25172730083246064
Egyed260227300833371104138178
M,280027300835569
Jurczak28892730083246384115146180210
W,312027300835767
et320827300833456
al.32852730083324760
Acalabrutinib336627300834172106121153193215253276291329344384
±3770273008342
Obinutuzumab214028300834888104143181204243273312371404444
Vs260528300833662
Obinutuzumab268828300834888104143181204243273312371404444
+3153283008342
Chlorambucil32162830083417995134156190249289328360376392
in362928300831453
Treatment-Naive37032830083335186214029300833152109143181202221266298312344377
Chronic25292930083407797133171185217
Lymphocytic275829300833158116154191229261293317332363
Leukemia:313329300833165101131164221235266278
6-Year34232930083345789119150170
Follow-3606293008331688398135185206
-up21403030083216099
of225430300833757
Elevate-TN.23263030083334883115148169203226256303316
Blood.26573030083365190128168181
2023;142(Supplement285330300833469101136148178209241259290328367407422457515550588610
1):636-636.3478303008334496196130164188225259293307
32.21403130085367085
Chiang22383130083407791123160198
CL,24493130083407184
Hu254531300834582
EY,26393130083336977
Chang272831300834078109146185
L,292531300833245
et298331300833355
al.30513130083324658
Leukemia-initiating312231300833265102132165222237268290305342357378393424445460497535
HSCs367031300834476116143
in39406300831451
chronic4001630083316787123160173204
lymphocytic42156300831545102139176213244276299313344
leukemia4569630083154884113145201215246
reveal4825630083215384117147161
clonal4997630083304481118148162
leukemogenesis5170630083154884113145201238276309345379404418442
and39407300833268106
differential405773008338527190123143176213233248279293
drug4361730083385895133
sensitivity.4505730083266097122136157171203217239271281
Cell4797730083397286100
Reports.49097300833568107144165188215227
2022;40(3):111115.5148730083336698132143177211230262279289318345371398424453464
33.3940830085367185
Rossi40388300833573100126141
D,41928300834556
Spina4260830083337187125157
V,44298300833645
Deambrogi44868300834681112170209230267307322
C,48218300833952
et48868300833456
al.4955830083314759
The50278300833372107
genetics51468300833873111146168183215242
of54018300833756
Richter54708300833551821203940930083225678
syndrome40399300832760100139161199258294
reveals4354930083215689124156172199
disease4574930083395481117149176212
heterogeneity4807930083387497131153191231267306341357380414
and52439300833271110
predicts5374930083406297137152185210238
survival39401030083266384119135168200216
after41711030083325176110131
transformation.43171030083224376114141161198220278311332348386424437
Blood.47701030083355189128167180
2011;117(12):3391-3401.496610300833468100127136166193223239271301319330366399432464483515550586618628
34.39401130085367388
Parry40441130083356788110144
EM,420311300833388101
ten43201130083215593
Hacken442811300834577109139173211
E,465511300833245
Wu471611300835794
CJ.48251130083406779
Richter49191130083365183121143177198
syndrome:51321130083265997136158195253288301
Novel544811300834583115149165
insights3940123008315537994132170192220
into41731230083145274111
the42971230083215994
biology44041230083395593109147186218
of463512300833857
transformation.47051230083214376114140160198219278310332347385424437
Blood.51551230083355189128167180
2023;blood.2022016502.53481230083356910213614818720324139401330083377790126160193228262294325359393426438
35.39401430085367185
Parry40381430083356788110144
EM,419414300833388101
Leshchiner43081430083326692130162200215253288309
I,463014300831427
Guièze46701430083448297131161195
R,487814300833549
et494014300833456
al.50091430083314760
Evolutionary508114300833365102118155178193231269301323356
history54501430083385379102139394015300832155
of401115300833756
transformation40841530083214376114140160198219278310332347385424
from45241530083184078136
chronic46761530083316990128166181213
lymphocytic490515300831547106145183222254288313328360
leukemia52811530083155088118152210225257
to555415300832259
Richter39401630083355183121142176197
syndrome.41531630083265897136157195253288300
Nature44681630083457799137158192
Medicine.467616300835489129144176191229264276
2023;1:12.496716300833569102136148178186216246259
36.39401730085357186
Nadeu403817300834475113147184
F,423417300833237
Royo428317300833572103139
R,443417300833548
Massoni-Badosa449417300835485111137174212226247284316354391417449
R,495517300833548
et501517300833355
al.50821730083314658
Detection515217300834579101133165188203240277
of544117300833756
early55091730083336484394018300831547
seeding40001830083266197136151189228
of424218300833756
Richter43121830083355183121142176197
transformation45231830083224376114140160198220278310332347385424
in496018300831553
chronic50271830083316990127166181213
lymphocytic525318300831547105145183221254288312328360
leukemia.39401930083155087118152210225257270
Nature42251930083457799137158192
Medicine.443319300835489129144176191229264276
2022;28(8):1662-1671.472419300833469101136149183217236270288300330361396430450481512545577587
37.39402030085367180
Davids404120300834678110126166192
MS,425420300835589102
Rogers437620300833675115150172199
KA,45962030083358095
Tyekucheva47122030083326095126165197236271304337
S,507020300833346
et513720300833456
al.52142030083324861
Venetoclax529620300833669108143166203236252285317
plus39402130083395592119
dose-adjusted407921300833977104139162195234249287313337371410
R-EPOCH45102130083355792127175217261
for47922130083185678
Richter48902130083365183122143177198
syndrome.51092130083265998137158196254289302
Blood.54312130083365290129169182
2022;139(5):686-689.394022300833468101136148178208242261294313324360395431454491527561572
38.39402330085367289
Frustaci40492330083325291117140173205221
AM,429023300834197110
Montillo442123300835493131153168184199237
M,467923300835468
Rossi476723300833674101127142
D,493023300834556
et500723300833456
al.50842330083314760
Results51642330083367198135151173201
of538523300833857
MOLTO,546223300835510313539402430083338091
a4052243008332
multicenter,410524300835795111134149182216254276310332342
open446724300833878114152
label,46402430083154887123139152
phase481324300833877110137172
II500624300831531
clinical50572430083324762101116148182197
trial5275243008322445992107
evaluating54032430083346710011615418739402530083223775115
venetoclax,407525300833267105140163200233249281313327
atezolizumab44222530083325488118156172187216255313346385
and482825300833270110
obinutuzumab49582530083387893132169192230260299357389429
combination54082530083316812716618239402630083387193109148187
in414826300831554
Richter42232630083365285123146180202
syndrome.44462630083266099139161199258294307
Journal477426300832464103124164197213
of500826300833757
Clinical50862630083415772111126159193208
Oncology.531526300834888121158175214254287297
2023;41(16_suppl):7502-7502.394027300833468101136147182212227259290328356393432472487507519552585619652672703736770803816
39.39402830085367185
Kittai4046283008335517498131147
AS,42132830083417588
Bond432228300833574112151
DA,44942830083458599
Huang461428300834482115153192
Y,482628300833644
et489028300833557
al.49672830083324861
Anti-CD19504828300834180101117139182227259289
Chimeric53582830083407893151186207223255
Antigen394029300834179101116155190228
Receptor418629300833570103136176198235256
T-Cell44602930083335194128143159
Therapy463729300833271106128161200231
for48862930083185678
Richter’s49822930083355082120142176197211236
Transformation:5236293008333508312114716720522728531733935439403030083377688
An404130300834079
International41333030083145274107129167199221236274313345360
Multicenter450630300835492107130145177210248270304325
Retrospective48443030083357092114151177216252284308324356390
Study.52473030083335492131162172
Blood.54323030083365189128168181
2023;142(394031300833468101136147177208241258
Supplement421431300833270109148164199257292330352
1):108-108.4581313008334496090122157180211242278291
VZDĚLÁVEJTE28358800401180342529681823100511701322143115821734
SE207458800401150302
ON-LINE245557700553270536688884105813241533
a28361800487179
získejte536618004871472323605286927799001064
kredity1674618004871682924566347208401001
◼získejte232690002681023736880024984132201293375423489571
2–129796880024998204284382
kreditů13966880024992158240330378444541
za19726880024984175
kurz21826880024992186252337
◼vyberte232716002681023737150024981167259341407474555
si9647150024969116
z11157150024985
různých12357150024966163247341427501595
medicínských37373600249141223314361435482577646737824897992
specializací14007360024969160242316363454503550635725799847
◼vzdělávejte232764002681023737630024981166256338386477558640688755837
se12457630024969151
dle14317630024991139221
svých16877630024969150237310405
časových3737840024974165234323405491565659
možností106778400249141231315410499569635683
www.solen.cz49087000016683167250277323383415469532567616672
On-line50597260016681144190222254316371
vzdělávání49817380016654110171225258318372433495527